ZG-5266 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase II drugs for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZG-5266’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZG-5266 overview

ZG-5266 is under development for the treatment of non-alcohol steatohepatitis (NASH) and primary biliary cirrhosis (PBS). It is formulated as a tablet and is administered by oral route. The drug candidate is developed based on drug stabilization technology (DST). It is a chemically new drug. It acts by targeting FXR receptor.

Suzhou Zelgen Biopharmaceutical overview

Suzhou Zelgen Biopharmaceutical (Zelgen) is a pharmaceutical company that carries out research and development, and production of innovative medicines. The company’s pipeline product includes donafenib tosylate tablets, topical recombinant human thrombin, jacktinib hydrochloride tablets, recombinant human thyroid-stimulating hormone for injection, jacktinib hydrochloride cream, ocaltinib capsules, magnesium obeticholate tablets and ZG19018. Its products are used in the treatment of nasopharyngeal carcinomas, myelofibrosis, thyroid cancer, liver cancer, non-small cell lung cancer, colorectal cancer, hemorrhage, and hepatobiliary diseases, among others. The company operates research and development activities in Kunshan, China; and California, the US. Zelgen is headquartered in Kunshan, Jiangsu, China.

For a complete picture of ZG-5266’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.